当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Olaparib plus bevacizumab improves progression-free survival in ovarian cancer.
The Lancet Oncology ( IF 41.6 ) Pub Date : 2020-01-09 , DOI: 10.1016/s1470-2045(20)30005-x
Elizabeth Gourd

The addition of maintenance olaparib to first-line standard therapy including bevacizumab significantly improves progression-free survival in patients with advanced ovarian cancer, according to a recent .

中文翻译:

奥拉帕利加贝伐单抗可改善卵巢癌的无进展生存期。

最近的一项研究表明,在包括贝伐单抗在内的一线标准疗法中添加奥拉帕尼维持治疗可显着改善晚期卵巢癌患者的无进展生存期。
更新日期:2020-01-31
down
wechat
bug